Phase I Trial of Brentuximab Vedotin With Re-induction Chemotherapy in Patients With Relapsed, CD30 Expressing, Acute Myeloid Leukemia (AML)
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Brentuximab vedotin (Primary) ; Cytarabine (Primary) ; Etoposide (Primary) ; Mitoxantrone (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- 12 Apr 2020 Status changed from active, no longer recruiting to completed.
- 20 Dec 2019 Results published in the Cancer
- 11 Aug 2019 Planned End Date changed from 1 Dec 2019 to 1 Feb 2020.